Wall Street brokerages expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce ($0.20) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Ironwood Pharmaceuticals’ earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.22). Ironwood Pharmaceuticals posted earnings per share of ($0.28) during the same quarter last year, which would suggest a positive year over year growth rate of 28.6%. The company is expected to announce its next quarterly earnings results on Thursday, August 2nd.
On average, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.67). For the next financial year, analysts anticipate that the company will report earnings of ($0.05) per share, with EPS estimates ranging from ($0.42) to $0.41. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Tuesday, May 1st. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The business had revenue of $69.16 million during the quarter, compared to the consensus estimate of $78.65 million. During the same quarter last year, the firm earned ($0.33) earnings per share. The business’s quarterly revenue was up 32.6% on a year-over-year basis.
A number of research firms have recently weighed in on IRWD. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 16th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Mizuho upgraded shares of Ironwood Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $16.00 to $24.00 in a report on Wednesday, May 2nd. Barclays boosted their target price on shares of Ironwood Pharmaceuticals from $16.00 to $20.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. Ironwood Pharmaceuticals has an average rating of “Hold” and an average price target of $19.44.
In other Ironwood Pharmaceuticals news, Director Julie Mchugh sold 1,500 shares of the business’s stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $17.62, for a total value of $26,430.00. Following the completion of the sale, the director now directly owns 92,631 shares of the company’s stock, valued at approximately $1,632,158.22. The transaction was disclosed in a filing with the SEC, which is available through this link. 7.63% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. LPL Financial LLC lifted its position in shares of Ironwood Pharmaceuticals by 16.3% in the 1st quarter. LPL Financial LLC now owns 21,160 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 2,959 shares during the period. Guggenheim Capital LLC lifted its position in shares of Ironwood Pharmaceuticals by 2.4% in the 1st quarter. Guggenheim Capital LLC now owns 188,974 shares of the biotechnology company’s stock worth $2,915,000 after purchasing an additional 4,372 shares during the period. Northern Trust Corp lifted its position in shares of Ironwood Pharmaceuticals by 0.3% in the 1st quarter. Northern Trust Corp now owns 1,561,766 shares of the biotechnology company’s stock worth $24,099,000 after purchasing an additional 4,613 shares during the period. Swiss National Bank lifted its position in shares of Ironwood Pharmaceuticals by 2.2% in the 1st quarter. Swiss National Bank now owns 223,500 shares of the biotechnology company’s stock worth $3,449,000 after purchasing an additional 4,900 shares during the period. Finally, Chicago Equity Partners LLC lifted its position in shares of Ironwood Pharmaceuticals by 3.3% in the 1st quarter. Chicago Equity Partners LLC now owns 220,750 shares of the biotechnology company’s stock worth $3,406,000 after purchasing an additional 7,070 shares during the period.
Shares of Ironwood Pharmaceuticals traded up $0.17, reaching $19.12, during trading hours on Friday, MarketBeat reports. The company’s stock had a trading volume of 1,145,532 shares, compared to its average volume of 1,345,551. Ironwood Pharmaceuticals has a one year low of $12.89 and a one year high of $19.79. The company has a quick ratio of 4.40, a current ratio of 4.42 and a debt-to-equity ratio of -21.52. The company has a market cap of $2.88 billion, a PE ratio of -20.56 and a beta of 1.11.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.